United States · Health Care · USD (Millions) · Annual
Reported figures and Equlion model projections for the next 4 years.
Amounts in USD (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Apellis Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | |||
|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | 7.48% | 61.04% | 43.12% | 32.82% | 27.4% |
|---|---|---|---|---|---|
| ROA | 2.28% | 26.27% | 24.01% | 21.22% | 19.49% |
| Gross Margin | 100% | 88.5% | 88.36% | 88.07% | 88.1% |
| Net Margin | 2.23% | 29.92% | 31.42% | 32.37% | 33.81% |
| Total Assets | $1,075.26M | $1,400.44M | $1,782.65M | $2,205.72M | $2,682.11M |
| Net Income | $22.39M | $325.18M | $382.20M | $423.08M | $476.38M |